IFNL3Your two copies: rs12979860C/rs12979860C
CCFavorable response genotype
An immune gene that affects how well hepatitis C treatment works.
This result doesn't change the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Antivirals · AntiviralsExample report
Ribavirin
Copegus, Rebetol, Virazole
Use as directed
Your genes make this hepatitis C treatment more likely to work. You may be able to take it for a shorter time.
The genes behind this label
The guidelines read one gene for ribavirin. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
IFNL3Favorable response genotype
CPIC guideline
Evidence: strongRead the guideline (Clinical Pharmacogenetics Implementation Consortium, opens in a new tab)
- In plain words
- Your genes make this hepatitis C treatment more likely to work. You may be able to take it for a shorter time.
- What it means
- Approximately 70% chance for sustained virologic response (SVR) after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.
- What the guideline suggests
- Approximately 90% chance for SVR after 24-48 weeks of treatment. Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks). Weighs in favor of using PEG-IFN alpha and RBV containing regimens.
About ribavirin
Ribavirin is an oral antiviral used for chronic hepatitis C, always in combination with other antivirals.
- Used for
- Chronic hepatitis C, always with other antivirals
Others in antivirals
Compare all 5 antiviralsDon't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.